![](https://nordot-res.cloudinary.com/c_limit,w_800,f_auto,q_auto:eco/ch/images/1146791424717029419/origin_1.jpg)
Welcome to Benzinga’s psychedelic headlines roundup. This is our pick of must-read news items from the last two weeks of March 2024.
See previous edition Psychedelics Headlines: Substitution Survey, Frank Herbert’s Magic Mushrooms, Celestial Plans And News Review
Research
- Psychedelic Therapy as a Form of Life (original read,)
- Scoping Review: The Role of Psychedelics in the Management of Chronic Pain (original read.)
- Improvements in well-being following naturalistic psychedelic use and underlying mechanisms of change in older adults: A prospective cohort study (original read.)
- Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression (original read.)
- Exploring the discourses around microdosing psychedelics within the r/microdosing online community (original read.)
- UK medical students’ self-reported knowledge and harm assessment of psychedelics and their application in clinical research: a cross-sectional study (original read.)
- Cultural Divergence in Psychedelic Use among Medical Students: An ESPAD-Adapted Survey among Poles and Iraqis (original read.)
- Structure-activity relationships of serotonergic 5-MeO-DMT derivatives: insights into psychoactive and thermoregulatory properties (original read.)
- Safety pharmacology of acute psilocybin administration in healthy participants (original read.)
- First Proof that Psilacetin is a Prodrug of Psilocin, coverage by Psychedelic Science Review.
Come and learn all about the latest trends in the cannabis sector at our upcoming Benzinga Cannabis Capital Conference!
![](https://nordot-res.cloudinary.com/c_limit,w_800,f_auto,q_auto:eco/ch/images/1146791498877174772/origin_1.gif)
Tune In, Get Smart
- "The Psychedelic Evangelist," on belated, respected field researcher Dr. Roland Griffiths by The New York Times (read.)
- "The FDA Backdoor to MDMA Rescheduling," by Vincent Joralemon for Harvard's Petrie Flom Center (read.)
- "‘Get on Your Knees' -Alberta Cops Raid Home Over Ayahuasca Delivery," by Mattha Busby for Filtermag (read.)
- "Cops Demand Access to Psychedelic Assisted Treatment at the United Nations," by Drogriporter (read.)
- "RFK Jr’s maloca of mystical politics" (read) and "Five reservations about psychedelic therapy," by researcher Jules Evans (read.)
- "Through the Psychedelic Looking Glass," by Winston Ross for New Lines mag (read.)
- "Psychedelic Theodicy – Denying Psychedelics' Potential for Harm," By Sam Woolfe for The Chemical Collective (read.)
- Cognitive impairment, dementia, Alzheimer's and psychedelics: 5 Questions for researcher Albert Garcia-Romeu by The Microdose (read.)
- Spiritual Health Practitioners Bring ‘Unique, And Uniquely Valuable' Expertise To Psychedelic-Assisted Therapy, Study Says – by Marijuana Moment (read.)
- "The Teachings of the Chacruna Plant," by DoubleBlind (read.)
- "The Importance of Ethnobiology: Ayahuasca Sustainability, Biognosis, and a Balanced Coexistence between Humanity and Nature," by Michael Coe for the McKenna Academy (read.)
- BBC's "People Fixing the World" podcast episode on magic mushrooms and mental health (listen.)
- Psychedelics Today's new podcast episode: "Reflections from Shulgin Farm: Psychedelics, Legacy, and the Spirit of Discovery" (listen.)
- Prof. David Nutt discussed the roadblocks and breakthroughs in psychedelic therapy at Mind Body Health & Politics podcast (listen.)
- New Stanford survey aims to understand more about people's exposure to media related to psychedelics (participate.)
Panorama Pulse
- Usona Institute announced the launch of its Phase 3 clinical trial on psilocybin as Major Depressive Disorder treatment.
- Rose Hill has partnered with the University of Guelph to research psilocybin mushrooms' potential for autism in the adolescent brain.
- Compass Pathways (NASDAQ:CMPS) board chair and co-founder George Goldsmith and co-founder Ekaterina Malievskaia have stepped down from the board of directors.
- Cybin (NYSE:CYBN) announced the closing of its oversubscribed private placement of $150 million.
- Cortexa would be the first clinic to supply psilocybin under the Australian Authorized Prescriber's Scheme.
- Filament Health (OTC:FLHLF) announced it is now shipping its botanical psilocybin to four countries for clinical research purposes.
- FSD Pharma (NASDAQ:HUGE) and iNGENu CRO signed an agreement to conduct a clinical study on the safety and efficacy of multiple ascending doses of Lucid-21-302 (Lucid-MS.)
- Red Light Holland (OTC:TRUFF) Happy Caps’ mushroom home-grow kits are now available in over 270 retail stores across Canada. MISTERCAP was selected by Urban Outfitters for nationwide distribution.
- Clearmind Medicine’s (NASDAQ:CMND) psychedelic-based treatment was granted a divisional patent approval in China, plus the company submitted an international patent application for preventing and treating depression.
- PharmAla's (OTC:MDXXF) novel MDMA-like molecule a P-1 received patent allowance from the U.S. Patent and Trademark Office.
- Silo Pharma (NASDAQ:SILO) filed a U.S. patent covering its ketamine implant targeting fibromyalgia and chronic pain.
Hosted at the Diplomat Beach Resort April 16- 17, the Benzinga Cannabis Capital Conference promises strong networking opportunities, as well as the chance to gain invaluable insights and foster growth in the cannabis industry. Renowned for its cutting-edge discussions and profound impact on the future of cannabis, this conference stands as the premier event of the year for industry professionals. Get your tickets now on bzcannabis.com – Prices will increase very soon!
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.